ArticleeLife2020
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 182 citations in OpenAlex.
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Review
- Redesign of TALE proteins for DNA-templated assembly of protein fibers.Nature communications · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Article
- Engineering complexity into protein-based biomaterials for biomedical applications.Nature reviews. Materials · 2026Article
- Biomimetic peptide self-assembly: interfacing with biomacromolecules to regulate cellular signaling.Experimental & molecular medicine · 2026Review
- Stabilization of the H5 clade 2.3.4.4b hemagglutinin improves vaccine-elicited neutralizing antibody responses in mice.Science translational medicine · 2026Article
- De novo protein design: a transformative frontier in clinical protein applications.Journal of translational medicine · 2026Review
- Hemagglutinin-displaying influenza nanovaccines: progress and promise.Nanomedicine (London, England) · 2026Review
- Stimuli-triggered formation ofCell biomaterials · 2026Article
- De novo design of protein nanoparticles with integrated functional motifs.bioRxiv : the preprint server for biology · 2026Article
- Immunogenicity Enhancement via Self-Assembled mi3 Nanoparticles Displaying ESAT-6 Antigen.International journal of nanomedicine · 2026Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.Research square · 2025Article
- Inhibition of ice recrystallization with designed twistless helical repeat proteins.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Computational design of bifaceted protein nanomaterials.Nature materials · 2025Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.bioRxiv : the preprint server for biology · 2025Article
- Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 Vaccines.Vaccines · 2025Article
- Local structural flexibility drives oligomorphism in computationally designed protein assemblies.Nature structural & molecular biology · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 2 countries.
George Ueda *Department of Biochemistry, University of Washington, Seattle, United States.ORCID 0000-0002-9792-7149
Aleksandar Antanasijevic *Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, United States.ORCID 0000-0001-9452-8954
Jorge A FallasDepartment of Biochemistry, University of Washington, Seattle, United States.
William ShefflerDepartment of Biochemistry, University of Washington, Seattle, United States.
Jeffrey CoppsDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, United States.
Daniel EllisDepartment of Biochemistry, University of Washington, Seattle, United States.
Geoffrey B HutchinsonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Adam MoyerDepartment of Biochemistry, University of Washington, Seattle, United States.
Anila YasmeenDepartment of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, United States.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, United States.
Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, United States.
Matthew J BickDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID 0000-0002-9585-859X
Banumathi SankaranBerkeley Center for Structural Biology, Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley Laboratory, Berkeley, United States.
Rebecca A GillespieVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Philip Jm BrouwerAmsterdam UMC, Department of Medical Microbiology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-2902-7739
Peter H ZwartBerkeley Center for Structural Biology, Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley Laboratory, Berkeley, United States.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID 0000-0002-6019-8675
Masaru KanekiyoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.ORCID 0000-0001-8112-0853
Rogier W SandersDepartment of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, United States.
John P MooreDepartment of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, United States.
Per Johan KlasseDepartment of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, United States.ORCID 0000-0001-8222-278X
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, United States.ORCID 0000-0001-7153-3769
Neil P KingDepartment of Biochemistry, University of Washington, Seattle, United States.
David BakerDepartment of Biochemistry, University of Washington, Seattle, United States.ORCID 0000-0001-7896-6217
University of Washington · USCornell University · USNational Institutes of Health · USScripps Research Institute · USLawrence Berkeley National Laboratory · USAmsterdam University Medical Centers · NLFrederick National Laboratory for Cancer Research · USHoward Hughes Medical Institute · US
Funding
Influenza Vaccine Research and DevelopmentZIAAI005003 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2009 to 2025
$89.8MStructural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4MUser Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6MY-FAMILY POLYMERASES AND CO-FACTORS IN TRANSLESION REPLICATIONP41RR015301 · NCRR · CORNELL UNIVERSITY ITHACA · PI EISENBERG, DAVID · 2001 to 2011
$28.2MOverall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3MAcquisition of a high resolution, high throughput cryo-electron microscopeS10OD023476 · OD · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M · 2017 to 2017
$2.0MA Pixel Array Detector System for Small Angle X-ray ScatteringS10OD018483 · OD · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI CLASSEN, SCOTT · 2014 to 2014
$998kBill and Melinda Gates Foundation OPP1111923Bill and Melinda Gates Foundation OPP1115782Bill and Melinda Gates Foundation OPP1120319Bill and Melinda Gates Foundation OPP1156262National Science Foundation CHE 1629214NCRR NIH HHS P41 RR015301NIAID NIH HHS P01 AI110657NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P41 GM103403NIH HHS S10 OD018483NIH HHS S10 OD023476U.S. Department of Energy DE-AC02-05CH11231
Abstract
Multivalent presentation of viral glycoproteins can substantially increase the elicitation of antigen-specific antibodies. To enable a new generation of anti-viral vaccines, we designed self-assembling protein nanoparticles with geometries tailored to present the ectodomains of influenza, HIV, and RSV viral glycoprotein trimers. We first
Indexed as
Immunity, HumoralAntigens, ViralCryoelectron MicroscopyGlycoproteinsHumansInfluenza VaccinesNanoparticlesVaccinationAntigens, ViralGlycoproteinsInfluenza VaccinesBL21B lymphocytescomputational biologyE. coliHEK293FhumanimmunologyinflammationLemo21systems biologyvirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.